Pharming Group Report on Preliminary Financial Results for 2016
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the full year ended 31 December 2016.
2017
2016
Pharming announces completion of acquisition of all North American commercialisation rights for RUCONEST® from Valeant
Operational updatesPharming Group N.V. today announces that it has completed a definitive agreement to acquire all North American commercialisation rights for its own product, RUCONEST® (recombinant human C1 esterase inhibitor), including all rights in the US, Mexico and Canada, from certain subsidiaries of Valeant Pharmaceuticals International, Inc. (“Valeant”) (NYSE/TSX: VRX).
Pharming announces completion of financing for RUCONEST® North American Rights Acquisition
Operational updatesPharming Group N.V. today announced that it has closed a new financing round, comprising three financial instruments and a rights issue, providing a total of €104 million before costs.
Prospectus 2016
Financial updatesProspectus 2016 is available for download.
Pharming Launches Rights Issue to raise €12.1 million as part of RUCONEST® North American Rights Acquisition Financing
Financial updatesPharming Group N.V. announces the launch of a 1 for 7 Rights Issue of up to 58,943,624 shares to raise approximately €12.1 million to existing shareholders its financing plans to enable the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as announced on 9 August 2016 (the “Transaction”).
Pharming Announces Financing Plans for Closing of RUCONEST® North American Rights Acquisition
Financial updatesPharming Group N.V. announces its financing plans to enable the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as announced on 9 August 2016.